Active Ingredient: Alteplase
Alteplase is indicated for thrombolytic treatment in acute myocardial infarction.
90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h after symptom onset.
3 h dose regimen: for patients in whom treatment can be started between 6-12 h after symptom onset provided that the diagnosis has been clearly confirmed.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
100 mg
100 mg once every day
90 minutes (accelerated) dose regimen for patients with acute myocardial infarction, in whom treatment can be started within 6 hours after symptom onset:
| Concentration of alteplase 1 mg/ml | Concentration of alteplase 2 mg/ml | |
|---|---|---|
| ml | ml | |
| 15mg mg as an intravenous bolus | 15 | 7,5 |
| 50mg as an infusion over 30 minutes | 50 | 25 |
| followed by an infusion of 35 mg over 60 minutes until the maximal dose of 100 mg | 35 | 17,5 |
In patients with a body weight below 65 kg the dose should be weight adjusted according to the following table:
| Concentration of alteplase 1 mg/ml | Concentration of alteplase 2 mg/ml | |
|---|---|---|
| ml | ml | |
| 15 mg as an intravenous bolus | 15 | 7,5 |
| ml/kg bw | ml/kg bw | |
| and 0.75 mg/kg body weight (bw) over 30 minutes (maximum 50 mg) | 0,75 | 0,375 |
| followed by an infusion of 0.5 mg/kg body weight (bw) over 60 minutes (maximum 35 mg) | 0,5 | 0,25 |
Intravenous
100 mg
100 mg once every day
3 h dose regimen for patients, in whom treatment can be started between 6 and 12 hours after symptom onset:
| Concentration of alteplase 1 mg/ml | Concentration of alteplase 2 mg/ml | |
|---|---|---|
| ml | ml | |
| 10 mg as an intravenous bolus | 10 | 5 |
| 50 mg as an infusion over the first hour | 50 | 25 |
| ml/30 min | ml/30 min | |
| followed by infusions of 10 mg over 30 minutes until the maximal dose of 100 mg over 3 hours | 10 | 5 |
In patients with a body weight below 65 kg the total dose should not exceed 1.5 mg/kg.
The maximum dose of alteplase is 100 mg.
Antithrombotic adjunctive therapy is recommended according to the current international guidelines for the management of patients with ST-elevation myocardial infarction.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
